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Our understanding of body composition (BC) variability in contemporary populations has
significantly increased with the use of imaging techniques. Abnormal BC such as sarcope-
nia (low muscle mass) and obesity (excess adipose tissue) are predictors of poorer prognosis
in a variety of conditions or clinical situations. As a catabolic illness, a defining feature of
cancer is muscle loss. Although the conceptual model of wasting in cancer is typically con-
ceived as involuntary weight loss leading to low body weight, recent studies have shown
that both sarcopenia and cachexia can be present with obesity. The combination of low
muscle and high adipose tissue (sarcopenic obesity) is an emerging abnormal BC pheno-
type prevalent across the body weight, and hence BMI spectra. Sarcopenia and sarcopenic
obesity in cancer are in most instances occult conditions, which have been independently
associated with higher incidence of chemotherapy toxicity, shorter time to tumour progres-
sion, poorer outcomes of surgery, physical impairment and shorter survival. Although the
mechanisms are yet to be fully understood, the associations with poorer clinical outcomes
emphasise the value of nutritional assessment as well as the need to develop appropriate
interventions to countermeasure abnormal BC. Sarcopenia and sarcopenic obesity create
diverse nutritional requirements, highlighting the compelling need for a more comprehen-
sive and differentiated understanding of energy and protein requirements in this heteroge-
neous population.
Sarcopenia: Obesity: Sarcopenic obesity: Body composition: Nutritional assessment:
Cancer: Nutritional status: Muscle: Lean body mass: Lean soft tissue
Body composition (BC) is a science that explores nutri-
tional status in view of the different contributions of
lean v. adipose tissue and its impact on health. The fast
growing evidence of the importance of BC assessment
may be attributed to the development of new in vivo tech-
nology and the resulting identification of abnormal BC
phenotypes that can, in turn, negatively impact prognosis
in any population. Here, we will briefly discuss recent
advances in BC assessment, focusing on the prevalence
and significance of these abnormal phenotypes in
patients with cancer. Additionally, we will contextualise
abnormal BC in view of the need for targeted nutrition
interventions. Although the focus of this paper is oncol-
ogy patients, we argue that issues hereby discussed are
broadly relevant to other populations that, like cancer,
have chronic diseases characterised by older age and
inflammation and where concurrently obesity also
occurs. These include, but are not limited to chronic ob-
structive pulmonary disease(1,2), insulin resistance/type II
diabetes(3), cirrhosis(4,5), rheumatoid arthritis(6) and con-
gestive heart failure(7).
Variability in body composition: a new face of an old
problem
When one is asked to imagine how abnormal BC looks
like in cancer, the idea of a cachectic looking, extremely
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emaciated person would likely be conceived by most peo-
ple. As a public person, Steve Jobs’ weight loss towards
the end of his cancer disease trajectory was a classic ex-
ample of how terminal illness is pictured. Weight loss
(and muscle loss) is an important component of cancer,
particularly advanced cancer and is observed as part of
the conceptual model of cancer progression. This trajec-
tory is characterised by involuntary weight loss that
increases exponentially in incurable cancers with a not-
able acceleration in the last few months prior to
death(8), a process also known as cancer cachexia.
Cancer cachexia can nonetheless manifest without the
concurrent phenotype of emaciation. Medical oncolo-
gists nowadays face a new issue as 40–60 % of their
patients present with excess body weight (overweight
and obesity) at the time of cancer diagnosis(9).
Nonetheless, obesity does not preclude the presence of
cancer cachexia and can indeed mask its appear-
ance(10,11), a concept that has been changing paradigms
in oncology research and practice. This new face of an
old problem was first identified with the use of BC ana-
lysis, which looks beyond body weight and BMI and
quantifies the different proportions of lean v. adipose tis-
sue within a unit of body weight(11).
Computerised tomography: an opportunistic tool
Our understanding of BC research in cancer has sub-
stantially advanced due to the use of computerised
tomography (CT) imaging scans. These images are
readily available from electronic libraries of medical
images taken for cancer diagnosis and prognostic
follow up(12). CT images can be retrieved for the add-
itional purpose of BC analysis providing accurate and re-
liable information on muscle and different adipose tissue
depots at the third lumbar vertebra cross-sectional area
(Fig. 1), an area chosen as the best correlate to whole
BC(13). Using image specific analysis software (free-of-
charge and paid): SliceOMatic, Tomovision; MeVislab,
MeVis Medical Solutions AG; UltraVisual, UltraVisual
Medical Systems Inc; ImageJ, National Institutes of
Health; OsiriX, Pixmeo; analyzer Synapse Vincent 3D
image analysis system, Fujifilm Medical, among others,
tissue marking and automated computation can be
accomplished. In addition to the availability of the
image and the software for its analysis, trained personnel
are also essential for accurate and reliable evaluation
(note a radiologist is not required). These methods are
highly reproducible, and have minimal additional cost.
Importantly, automated software is currently being
developed for rapid and practical imaging analysis(14).
Two brief videos containing an overview of the third
lumbar vertebra CT analysis for BC using two different




The procedures for image analysis include finding the
landmark of interest (third lumbar vertebra) and retrieving
it for analysis (Digital Imaging and Communications in
Medicine, DICOM format) by utilising the software of
choice or a specific browser (e.g. iQ-VIEW, PACS, which
are free DICOM viewers). Next, the image is uploaded
in the software of choice for tissue analysis, where muscle
and adipose tissue can be evaluated based on differences
in pre-established measures of Hounsfield unit attenuations
as follows: −29 to +150 for skeletal muscle(15), −190 to
−30 for subcutaneous and intermuscular adipose tissue(15)
and −150 to −50 for visceral adipose tissue(16).
Defining divergent behaviour of muscle and adipose
tissue in cancer
Using CT image analysis we, and others, were able to
identify a great variability of BC in contemporary cancer
patients(10,17–20), Fig. 2. As illustrated in this figure,
patients with any given BMI can present with severe
muscle depletion (sarcopenia) or with normal muscle
mass. Alternatively, individuals may present with BMI
of different (and extreme) categories, yet have exactly
the same amount of muscle mass, Fig. 3.
As a catabolic illness, a defining feature of cancer is
muscle loss. Low muscle mass, also termed sarcopenia
is common in people with cancer regardless of stage
(i.e. from curative to palliative). In fact, the overall
prevalence of sarcopenia in the studies hereby reviewed
is about 40–50 % in people with newly diagnosed cancer,
considerably higher than about 15 % prevalence in
healthy individuals of similar age (median 65 years)(21).
Since only about 10 % of cancer patients are clinically
underweight(20), this widespread phenomenon of muscle
depletion is independent of body weight or fat mass.
Fig. 4 illustrates the widespread distribution of sarcope-
nia across the BMI spectrum using population cohort
data of patients with colorectal cancer treated at a re-
gional cancer centre in Alberta, Canada. Sarcopenia
increased at all lower BMI strata, but was also substan-
tially present at higher BMI. As discussed previously,
sarcopenia can coexist with obesity (sarcopenic obesity),
compounding health consequences for physical function
and survival in cancer(11,22).
Sarcopenia is different from cancer-associated cach-
exia. In cancer cachexia diagnoses, sarcopenia needs to
Fig. 1. (Colour online) Cross-sectional area at the third lumbar
vertebra (L3) region analysed for body composition. Note muscle
green area termed intermuscular adipose tissue represents both
intra- and extra-myocellular lipid.
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be defined in conjunction with weight loss(23). The under-
standing of abnormal BC in cancer has also impacted the
definition of cancer cachexia. The international consen-
sus group definition now recognises cancer cachexia as a:
‘Multifactorial syndrome defined by an ongoing loss of skel-
etal muscle mass (with or without fat mass) that cannot be
fully reversed by conventional nutritional support and leads
to progressive functional impairment‘(emphasis added)(23).
Therefore, sarcopenia, sarcopenic obesity and cancer
cachexia can manifest at any given BMI and body
weight, which may be undetected by use of these an-
thropometric tools alone, hence the importance of
additional assessment using BC techniques. The most
commonly used cutpoints to define sarcopenia have
been developed in obese patients with lung or gastro-
intestinal cancer using optimal stratification analysis.
The gender-specific values below which patients are
categorised as sarcopenic are 52·4 cm2/m2 for men and
38·5 cm2/m2 for women(10). These cutpoints have been
used in many different cohorts of patients and clinical
populations, consistently demonstrating an association
with patient prognostication(2,4,24). In the optimal stratifi-
cation analysis approach, patients are stratified from
least to most muscular and a gender-specific threshold
for increased risk of a clinical outcome (in this case
Fig. 2. (Colour online) Trapezium model of body composition in cancer illustrating the variability in
body composition in patients with identical BMI. Male patients with lung or colorectal cancer.
Muscle cross-sectional area (cm2): (a) = 28·6, (b) = 51·5, (c) = 40·3, (d) = 52·8, (e) = 35·3, (f) = 51·3, (g) =
33·7, (h) = 70·7, (i) = 50·1 and for total adipose tissue cross-sectional area (cm2/m2): (a) = 2·7, (b) = 5·0,
(c) = 3·5, (d) = 27·9, (e) = 27·9, (f) = 146·8, (g) = 161·2, (h) = 175·3, (i) = 218·3. Cancer patients of the
same height, weight and hence BMI category can present with very distinct amount of skeletal
muscle mass. Non-sarcopenic patients are depicted on the left side, while sarcopenic patients are
shown on the right side. This figure also illustrates how overweight and obese cancer patients can
present with severe muscle depletion, highlighting how sarcopenic obesity is a potential hidden
condition to health care professionals.
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survival) identified. Using the same approach, Martin
et al.(20) have more recently published BMI-specific
cutpoints for sarcopenia diagnosis (underweight and nor-
mal weight: <43 cm2/m2 for men and <41 cm2/m2 for
women; overweight and obese: <53 cm2/m2 for men
and <41 cm2/m2 for women) Since these cutpoints are
BMI-specific, they provide a better indication of the
prevalence of sarcopenia in non-obese individuals (com-
pared with Prado et al.(10) defined for obese individuals
only). It is important to note that the cutpoints men-
tioned in this paragraph were developed in a North
American population, which may limit its use in different
ethnicities(25).
Although similar to the Prado et al. cutpoints(10),
the ones proposed to diagnose sarcopenia by the cach-
exia consensus group(23) are not the same. The consensus
group cutpoints(23) are the conversion from kg/m2 to
cm2/m2 of Baumgartner’s dual-energy X-ray absorpti-
ometry-assessed sarcopenia cutpoints defined for elderly
individuals: <7·26 kg/m2 for men and <5·45 kg/m2 for
women(26). These are converted to <55 cm2/m2 for men
and <39 cm2/m2 for women, as reported in Fearon
et al.(23) using a regression equation previously pub-
lished(27). In addition to dual-energy X-ray absorpti-
ometry and CT cutpoints, the international consensus
group has also suggested cutpoints developed using bio-
electrical impedance analysis, and for surrogate measure-
ments of BC using the mid upper-arm muscle area(23).
Sarcopenic obesity has been most commonly identified
using a combination of any sarcopenia cutpoints
defined earlier in conjunction with BMI cutpoints (pro-
vided very muscular individuals can be identified by the
CT image and are not incorrectly classified as
obese)(10,20,24,28,29).
Implications of abnormal body composition
Despite the variability of available BC assessment
tools and cutpoints, sarcopenia and sarcopenic obesity
have been consistently associated as predictors of un-
favourable outcomes in oncology patients. Selected
examples will be discussed in this section.
Treatment toxicity
One of the very first research questions regarding the
potential impact of abnormal BC on cancer prognosis
was related to the issue of individualising chemotherapy
treatment(30). Most chemotherapy drugs are adminis-
tered based on body surface area, which is a calculation
that only accounts for height and weight. Therefore, indi-
viduals with identical height, weight and hence body sur-
face area (as presented in each BMI category in Fig. 2)
would consequently be receiving exactly the same
amount of chemotherapy drug(31). Such practice ignores
the large individual variability in muscle mass and hence
lean tissue compartment, where pharmacokinetics (drug
metabolism) occurs(32–35). This concept has been exten-
sively reviewed previously and we refer the reader to
other articles for a more detailed discussion(31,32).
Based on this concept, the original hypothesis was that
a sarcopenic person would receive a large amount of
drug for a small lean tissue compartment; increasing
this person’s risk for developing dose limiting toxicity
(DLT)(31). DLT is an unfavourable and undesirable out-
come of chemotherapy, which leads to treatment termin-
ation, discontinuation, hospitalisation or death. The
original hypothesis was investigated using several differ-
ent studies with different chemotherapy drugs and in
individuals with different cancer types(31,36). In a recently
published paper by Anandavadivelan et al.(28), DLT was
investigated in seventy-two patients receiving
neo-adjuvant therapy for oesophageal cancer.
Unfortunately, absolute values of muscle mass were not
stratified by gender when comparing those presenting v.
not presenting with DLT. Nonetheless, using a gender-
specific definition of sarcopenia, they showed that sarco-
penic obese presented with higher DLT compared with
their non-sarcopenic obese counterparts (OR 5·54;
(95% CI 1·12, 27·44).
Collectively, these studies show that sarcopenia
(withor without concurrent obesity) is an independent
predictor of severe toxicity, affecting cancer treatment
and its outcomes. The same hypothesis holds true
for studies on targeted chemotherapy agents(19,37)
(Fig. 5) and for hydrophobic agents, where both muscle
and adipose tissue may play a role in predicting
toxicity(34).
Therefore, there is enough evidence to suggest these
patients behave as if they were overdosed. Future
dose-escalating studies personalised by BC will illus-
trate the value of personalising chemotherapy treat-
ment(38) using BC, and the respective impact on
decreasing the risk of DLT consequently increasing the
number of planned chemotherapy cycles in sarcopenic
patients.
In addition to cancer being a catabolic condition lead-
ing to muscle loss, cancer-treatment itself can impact BC.
Chemotherapy treatment can decrease muscle mass by
4·6 cm2(39) which is about 0·8 kg at the whole body
Fig. 3. (Colour online) Illustration of three male patients of different
BMI presenting with similar amount of muscle cross-sectional area
(skeletal muscle index = about 42·4 cm2/m2).
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level using the regression equation in Shen et al.(13):
whole body muscle mass = 0·166 × (CT measured skel-
etal muscle (cm2)) + 2·142, but using only the slope
since the line has a non-zero intercept.
Survival
We have pioneered the findings of sarcopenic-obesity as
an independent predictor of physical impairment (47 v.
26 % in non-sarcopenic obese, P = 0·005) and survival
Fig. 5. (Colour online) Summary of individual study studies relating sarcopenia with
dose-limiting toxicity; several antineoplastic therapies and cancer types
represented. 5FU (5-fluorouracil), colorectal cancer(30); Capecitabine, breast
cancer(42); Adjuvant FEC (%-fluorouracil, epirubicin, cyclophosphamide), breast
cancer(33); Sorafenib, renal cell cancer(37); Sorafenib, renal cell cancer(77); Sunitinib,
renal cell cancer(78); Vandetabin, advanced medullary thyroid carcinoma(79);
Fluoropyrimidine, colorectal cancer(80); Imatinib, gastrointestinal stromal tumour
(anaemia and fatigue)(81); ECX and CF (Epirubicin, Cisplatin, Capecitabine) and CF
(Cisplatin and 5-Fluorouracil), oesophagogastric cancer(82).
Fig. 4. (Colour online) Prevalence of sarcopenia (dots) in patients with stages I–IV colorectal cancer,
n 684. Consecutive patients referred to a medical oncology service in a regional cancer centre in
Alberta, Canada. Considering BMI categories, sarcopenia was prevalent in 74 % of underweight
patients, 42 % of normal weight, 39 % overweight, 24·4 % obese (all classes). Among the obese
individuals, sarcopenia was present in 28·8 % of class I, 18·2 % class II and 14·3 % of class III
obese patients. Sarcopenia defined using BMI-specific cutpoints(20). Data courtesy of Dr Vickie
Baracos, University of Alberta.
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in a population cohort of patients with lung or gastro-
intestinal cancer(10). Survival was shorter for sarcopenic
obese patients compared with non-sarcopenic obese (haz-
ard ratio (HR) 4·2; 95% CI 2·4, 7·2)(10). We have also
reported similar findings in sarcopenic patients with
hepatocellular carcinoma(40), and lung or colorectal can-
cer(41) and that sarcopenia is an independent predictor of
shorter time to tumour progression(42).
More recently, 2-year overall survival was lower in sar-
copenic patients with diffuse large B-cell lymphoma,
compared with the non-sarcopenic counterparts (46 v.
84 %, respectively) with a HR 3·22; 95 % CI 1·73,
5·98(43). Miyamoto et al.(44) investigated the prognostic
effect of sarcopenia in patients with stages I–III colorec-
tal cancer undergoing curative resection surgery.
Sarcopenia was an independent predictor of shorter
recurrence-free survival (HR 2·18; 95 % CI 1·20, 3·94)
and overall survival (HR 2·27; 95 % CI 1·15, 4·5). In a
separate study, the authors also showed that muscle
loss was similarly associated with poor prognosis in
patients with unresectable colorectal cancer(45). Muscle
loss >5 % after chemotherapy treatment was associated
with shorter overall survival (HR 2·08; 95 % CI 1·19,
3·62). Sarcopenia was also a significant predictor of over-
all survival in patients with urothelial cancer (HR 3·36;
95 % CI 1·9, 6·1)(46), hepatocellular carcinoma (HR 3·2;
95 % CI 1·28, 8·0)(47), and metastatic renal cell carcinoma
(HR 2·13; 95 % CI 1·15, 3·92)(48). Additionally, several
other recent studies have investigated the prognostic im-
pact of sarcopenia on survival on cancer (39,49–51); the
growing body of literature on the topic is impressive.
Broader implications
Much broader implications can be attributed to abnor-
malities in BC. Sarcopenia has been associated with the
development of postoperative infections, the need for in-
patient rehabilitative care, incidence of hospitalisation
and length of hospital stay as shown in Lieffers
et al.(17) and Peng et al.(52). More recently, Ida et al.(53)
reported a higher incidence of postoperative respiratory
complications among sarcopenic patients compared
with non-sarcopenic (15·5 v. 6·5 %, respectively, P =
0·01) and showed sarcopenia (OR 5·82; P = 0·0001) was
a risk factor for the occurrence of respiratory complica-
tion in patients with oesophageal cancer. In patients fol-
lowing pancreatectomy, sarcopenia was an independent
predictor of major grade III complications, length of
stay, intensive care unit admission, delayed gastric
emptying, and infectious, gastrointestinal, pulmonary
and cardiac complications(54). Similar results were
reported by van Vugt et al.(55) who demonstrated that
sarcopenia was associated with severe postoperative com-
plications in patients undergoing cytoreductive surgery
with hyperthermic intraperitoneal chemotherapy for
peritoneal carcinomatosis of colorectal cancer.
Cancer therapy can also lead to abnormal BC. As an
example, patients undergoing breast cancer therapy and
androgen deprivation therapy for prostate cancer de-
velop a pattern of fat gain with concurrent loss of lean
mass (i.e. sarcopenic obesity)(56). These patterns of
change have been linked to decreased quality of life,
decreased disease-free survival, increased risk of CVD,
increase risk of insulin resistance/diabetes, reduced bone
mass, increased risk of fractures at multiples sites and
also, metabolic imbalances, consequences likely related
to both sarcopenia and obesity(56–58). Additionally,
some drugs commonly used can also promote muscle
loss such as corticosteroids, statins and tyrosine kinase
inhibitors, as reviewed previously(36).
Impact of muscle radiodensity
Another metric associated with key health outcomes is
muscle radiodensity. Prado et al. were the first to report
an association between low muscle attenuation and sar-
copenia in cancer patients(10). Reduced muscle attenu-
ation is reflective of intermuscular adipose tissue or
poor ‘quality’ skeletal muscle. Aubrey et al.(59) intro-
duced a radiation attenuation map of paraspinal/psoas
muscles depicting the myoesteatosis phenomenon, a con-
cept illustrated in Fig. 6. This concept highlights that
skeletal muscle may contain areas of normal and reduced
attenuation; and that these reduced attenuation areas are
within radiodensity ranges of adipose tissue. Therefore
the ‘quality’ of the muscle may be affected with indivi-
duals having less than half of muscle falling within nor-
mal muscle attenuation areas. Importantly, low muscle
radiodensity is emerging as an important and in some
cases stronger predictor of clinical outcomes (compared
with muscle mass alone). In Sabel et al.(60) low (psoas)
muscle radiodensity was associated with disease-free
and distant disease-free survival (P = 0·04 and P=
0·0002, respectively). These results were supported by a
Martin et al.(20) study, where low muscle attenuation
was a powerful predictor of survival (HR 1·36, 95 % CI
1·2, 1·6), and more recently by Okumura et al.(50), who
showed low muscle quality associated with poor overall
(HR 2·5, P < 0·001) and recurrence free (HR 1·6; P=
0·004) survival.
The impact of abnormal body composition on nutritional
therapy
All of the implications of sarcopenia and sarcopenic-
obesity in cancer can be conceived as the potential clinic-
al benefits of reversing these abnormalities by nutritional
therapy. We now know cancer patients have anabolic
potential(61). Contrary to popular belief, sarcopenia in
cancer is reversible even in people of older age, decon-
ditioning, inflammation and concurrent comorbid
conditions(62). Evidence also shows that anabolic res-
ponsiveness is not suppressed by nutrition inter-
ventions(63–68). In spite of this evidence, recent
pharmacological studies on retention or gain of muscle
mass in cancer have failed to provide (or account for)
sufficient energy and protein to sustain muscle mass ac-
cretion(63,65). While the importance of adequate nutrient
intake is obvious, an important unanswered question
relates to the optimal energy and protein intakes during
cancer disease trajectory.
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Muscle loss in cancer is partially driven by increased
muscle protein catabolism, when substrate availability
(protein intake) is insufficient. Not only is a supply of
protein essential, but an adequate dose and balance of
calories and essential nutrients are required to support
maintenance or gain of muscle. The optimal amounts
of protein and calories are undefined for preventing or
treating sarcopenia in people with cancer. Protein intake
Fig. 6. (Colour online) Muscle radiodensity variability for psoas, erector spinae and quadratus lumborum at the third
lumbar vertebra. A1, B1 represent contrast enhanced images of computerised tomography images analysed for body
composition for two individual patients; A2 and B2 represent the pie chart of variability in muscle radiodensity
attenuation showing the percentage total tissue area within the ranges of adipose tissue (light blue, −190 to −30
Hounsfield Units, HU), normal attenuation muscle (red, +30 to +150 HU) and abnormal (reduced) attenuation muscle
in two ranges (dark blue, −29 to 0 HU; yellow, +1 to +29 HU). The patient on the right (B1) presents with a
significant amount of skeletal muscle lipid content and hence lower overall HU attenuation. This is indicative of
muscle myosteatosis which more than 50 % of the tissue area following in HU range for the adipose tissue.
Conversely, the patient on the left (A1) has the majority of tissue area within normal muscle radiation attenuation
values. This concept is presented in Aubrey et al.(59).
Fig. 7. (Colour online) (a) Correlation of lean mass (LM, which is primarily muscle mass) and body weight in patients
(n 684) with colorectal cancer (stages I–IV cancer) receiving treatment at a regional cancer centre in Alberta, Canada
and (b) variability in theoretical dose of protein per kg LM by body weight in the same cohort. The defect in defining
a person by body weight: a person of 80 kg (highlighted in red box) can have anywhere between about 30 and 70 kg
lean mass. This is a substantial difference. Example based on intake of 0·8 g protein/kg body weight/d, showing a
wide range in dose of protein/kg of LM. In the highlighted example, people weighing 80 kg who are fed 0·8 g protein/
kg/body weight would receive between 0·8 and 2·1 g protein/kg LM, depending on the amount of LM in their total
BW. Data courtesy of Dr Vickie Baracos, University of Alberta.
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by cancer patients is variable (0·2–2·7 g/kg)(69) and many
do not meet current dietary guidelines of 0·8 g/kg for
healthy individuals(70) or 1·0–1·5 g/kg for those with can-
cer(71–73). We previously reported that 35 % of cancer
patients had protein intakes below 1·0 g/kg(74) and that
protein intake correlated with muscle mass (r 0·4; P =
0·001) and lean mass (r 0·4; P = 0·003)(75).
Current protein and energy guidelines in cancer, and
across a broad spectrum of other chronic conditions, rec-
ommend daily ranges of intake adjusted by body weight.
This ignores the large variability of BC in contemporary
population extensively discussed earlier and also shown
in Fig. 7(a). As a theoretical example, patients who
weigh the same and are provided protein at 0·8 g/kg
body weight would receive anywhere between 0·8 and
2·1 g protein/kg lean mass, owing to differences in BC,
Fig. 7(b). The proposition that lean mass drives protein
requirements is widely accepted; thus adjusting dietary
targets by BC is more appropriate. The same logic can
be applied to energy recommendations, which estimate
25–35 kcal/kg per d for people with cancer(73) without
considering BC. A sarcopenic obese patient thus would
receive more calories than required, but less protein
than needed(11), leading to gains in fat mass that are
not associated with treatment success and longevity(10,76).
Current nutrition recommendations are inconsistent
with findings of variable BC and do not meet the physio-
logical needs of most cancer patients. At one end of the
spectrum, underweight patients have elevated protein
requirements due to their illness. They may receive ad-
equate energy but inadequate amounts or quality of pro-
tein, placing them at risk for protein malnutrition and
sarcopenia. In contrast, obese patients may have second-
ary pathologies related to their excess fat mass. They re-
quire tailored amounts and types of energy, targeted to
prevent increases in fat mass and worsening of problems
such as insulin resistance and lipid control. The obese pa-
tient may also have sarcopenia (sarcopenic obese), which
would increase their protein needs. Thus, dietary pre-
scriptions for energy and protein need to be discon-
nected. Their energy needs must relate to their obesity
and other comorbidities, with protein intake targeted to
protect muscle mass(11).
Conclusion
BC is variable within patients with identical body size.
Sarcopenia and sarcopenic obesity are prevalent, can
occur concurrently with cachexia and are prognostic for
poorer quality of life, longer length of hospital stay, re-
habilitation care, postoperative complication, survival,
among others. Given the high and increasing prevalence
of cancer and the high incidence of sarcopenia in people
with cancer, sarcopenia and its attendant health risks and
functional deficits are a significant problem potentially
affecting hundreds of thousands of cancer patients.
The variability in BC in contemporary cancer popula-
tion creates diverse nutritional requirements which have
nonetheless been established as a range of intake, with
no specific target for patients to achieve. Assuming
that protein and energy feeding may be done by body
weight ignores this variability in BC, promoting or en-
hancing the sarcopenic or sarcopenic obesity phenotype.
Dietary guidelines for people with cancer are not optimal
or evidence-based(11). The need is compelling for a more
comprehensive and differentiated understanding of en-
ergy and protein requirements in this heterogeneous
population. Future research should integrate nutritional
goals of energy retention and balance, for the develop-
ment of guidelines and recommendations targeting indi-
viduals with different physiological needs to prevent or
delay sarcopenia, and improve muscle mass while also
optimising fat mass.
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